Novo Holdings A/S’s 4D Molecular Therapeutics FDMT Stock Holding History

Novo Holdings A/S’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.2M	Sell	3,249,178 -401,559	-11%	-$3.91M	2.51%	15
2026 Q1	$34M	Hold	3,650,737	–	–	2.75%	16
2025 Q4	$27.4M	Buy	3,650,737 +1,650,737	+83%	+$16.7M	2.13%	18
2025 Q3	$17.4M	Hold	2,000,000	–	–	1.12%	23
2025 Q2	$7.42M	Buy	2,000,000 +50,000	+3%	+$176K	0.52%	24
2025 Q1	$6.3M	Buy	1,950,000 +450,000	+30%	+$2.12M	0.48%	24
2024 Q4	$8.36M	Hold	1,500,000	–	–	0.51%	27
2024 Q3	$16.2M	Buy	1,500,000 +100,000	+7%	+$1.66M	0.81%	27
2024 Q2	$29.4M	Hold	1,400,000	–	–	1.58%	19
2024 Q1	$44.6M	Sell	1,400,000 -100,000	-7%	-$2.55M	3.08%	10
2023 Q4	$30.4M	Buy	1,500,000 +300,000	+25%	+$3.95M	1.88%	21
2023 Q3	$15.3M	Buy	1,200,000 +200,000	+20%	+$3.35M	1.13%	27
2023 Q2	$18.1M	Buy	1,000,000 +300,000	+43%	+$5.52M	1.4%	26
2023 Q1	$12M	Buy	+700,000	New	+$13.6M	0.79%	34

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Novo Holdings A/S's FDMT Position: Q2 2026 in Review

Novo Holdings A/S reduced its 4D Molecular Therapeutics (FDMT) stake by 11% in Q2 2026, selling an estimated $3.91M and leaving 3,249,178 shares worth $43.2M. The position accounts for 2.51% of the portfolio, ranked #15.

Novo Holdings A/S first reported a position in FDMT in Q1 2023 and has held it in 14 quarters since. The position peaked at $44.6M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Novo Holdings A/S held 3,249,178 shares of 4D Molecular Therapeutics worth $43.2M as of Q2 2026.
Novo Holdings A/S sold 401,559 4D Molecular Therapeutics shares in Q2 2026, an estimated $3.91M.
4D Molecular Therapeutics made up 2.51% of Novo Holdings A/S's portfolio in Q2 2026, its #15 holding.
Novo Holdings A/S first reported a position in 4D Molecular Therapeutics in Q1 2023 and has held it in 14 quarters since.
Novo Holdings A/S's 4D Molecular Therapeutics position peaked at $44.6M in Q1 2024.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.